Antibody Drug Conjugates (ADCs) are the future of targeted cancer therapies. However, due to limitations to their mode of action, ADCs are not completely degraded with limited drug release restricting efficacy. ADC and drug metabolites remain entrapped with ADCs being recycled back outside the cells by multiple mechanisms.
The proprietary drug delivery platform enhances intracellular delivery, by breaking down endosomal membranes and promote endosome to cytosol escape, multiplying drug efficacy.
Numerous potential applications and indications are in development leveraging use of the drug delivery platform.
The platform is suitable to enhance the delivery of proteins, RNA and DNA with applications in Antibody-Drug Conjugates (ADCs) and Vaccines(Cancer and ID)
enhances intracellular delivery
multiplying drug efficacy
Suitable for Proteins, RNA, DNA, ADCs and VaccinesDrug delivery platform enhancing breakdown of endosomal membranes for drug efficacy